C0030956||peptide
C1999611||human β thymosin
C1254351||anti-biofilm agents
C4275190||Staphylococcus spp.
C0033809||Pseudomonas aeruginosa
C0003232||antibiotics
C0081786||biofilm
C3714514||infections
C3714514||infection
C2825055||recurrence
C4084937||antimicrobial peptides
C0003204||anti-infective agents
C0032071||planktonic
C0081786||biofilm
C1335533||fragment
C1999611||human thymosin β4
C2603343||studied
C1518960||conformations of the peptide
C0205099||central hydrophobic core
C0205100||peripheral
C3161035||models
C0684063||eukaryotic
C0030956||peptide
C1271650||antimicrobial activity
C0032071||planktonic
C0081786||biofilm
C4275190||Staphylococcus spp.
C0033809||P. aeruginosa
C1999611||human thymosin β4
C1335533||fragment
C0002518||EIEKFDKSKLK
C1149575||antibacterial activity
C0038170||staphylococcal
C0033809||Pseudomonas aeruginosa
C1325881||biofilm formation
C1335533||fragment
C1325881||biofilm formation
C1518960||conformations
C1999611||Human thymosin β4
C1335533||fragment
C1254351||lead compound
C0034861||recombinant derivatives
C0008003||pharmaceutical